Arthur Rottermann, an Inergetix CoRe user here in Switzerland, has sent me the following information which I’m sure will be of interest to all Inergetix users who work with frequencies and the new light array applicator will increase our possibilities in this field. Under the title of
Amplitude-modulated electromagnetic fields for the treatment of cancer:
discovery of tumor-specific frequencies and assessment of a novel therapeutic
the following article was published. It is especially interesting that patient-specific frequencies were used!
Cabinet Médical, Avenue de la Gare 6, Lausanne, Switzerland. firstname.lastname@example.org
PURPOSE: Because in vitro studies suggest that low levels of electromagnetic fields may modify cancer cell growth, we hypothesized that systemic delivery of a combination of tumor-specific frequencies may have a therapeutic effect. We undertook this study to identify tumor-specific frequencies and test the feasibility of administering such frequencies to patients with advanced cancer. PATIENTS AND METHODS: We examined patients with various types of cancer using a noninvasive biofeedback method to identify tumor-specific frequencies. We offered compassionate treatment to some patients with advanced cancer and limited therapeutic options. RESULTS: We examined a total of 163 patients with a diagnosis of cancer and identified a total of 1524 frequencies ranging from 0.1 Hz to 114 kHz. Most frequencies (57-92%) were specific for a single tumor type. Compassionate treatment with tumor-specific frequencies was offered to 28 patients. Three patients experienced grade 1 fatigue during or immediately after treatment. There were no NCI grade 2, 3 or 4 toxicities. Thirteen patients were evaluable for response. One patient with hormone-refractory breast cancer metastatic to the adrenal gland and bones had a complete response lasting 11 months. One patient with hormone-refractory breast cancer metastatic to liver and bones had a partial response lasting 13.5 months. Four patients had stable disease lasting for +34.1 months (thyroid cancer metastatic to lung), 5.1 months (non-small cell lung cancer), 4.1 months (pancreatic cancer metastatic to liver) and 4.0 months (leiomyosarcoma metastatic to liver). CONCLUSION: Cancer-related frequencies appear to be tumor-specific and treatment with tumor-specific frequencies is feasible, well tolerated and may have biological efficacy in patients with advanced cancer. More details you find here :http://clinicaltrials.gov/ct2/show/NCT00440934
Kiran’s Reply :
Thank you David and Arthur for this contribution. I will contact them to find out the details because what is unusual here are two words “compassionate treatment” and “tumor specific frequencies” because I know both are keys and expression of the same principle “To make therapy as personal as possible” and to get away from this generic approach of contemporary medicine that assumes “one color/ fabric/ size fits all”. We are making CoRe the most universal tool in the history of medicine, as I know health is based on the multidimensional of what it means to be an individual. (Paradoxically it is exactly the country that was founded with the vision and mission to promote individual freedom that now limit this freedom in the most essential areas like that of health care options.)
Compassion in healing means to find out what a client resonates with, what is of very personal concern to him, and CoRe is the tool to find it. Resonant frequencies are the energetic equivalent that are very unique to this particular body and again CoRe has the technology to uncover it. I can promis you that we are only at the beginning of this amazing journey and already CoRe 6.0 will go much further into the direction of bringing energy and information together because ony together they can truly match and modulate what we are.
AND CoRe goes one step further as we do not treat Organs or Diseases but that we give the informational support, nodulated on energy, that makes the difference on the informational and spiritual level, because we know that the control mechanism is there and only there.